title: Chromosomal radiosensitivity in patients with multiple sclerosis.
abstract: Multiple sclerosis is a clinically heterogeneous autoimmune disease leading to severe neurological disability. Although during the last years many disease-modifying agents as treatment options for multiple sclerosis have been made available, their mechanisms of action are still not fully determined. In the present study radiosensitivity in lymphocytes of patients with relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis and healthy controls was investigated. Whole blood cultures from multiple sclerosis patients and healthy controls were used to analyze the spontaneous and radiation-induced micronuclei in binucleated lymphocytes. A subgroup of patients with relapsing-remitting multiple sclerosis was treated with immunomodulatory agents, interferon β or glatiramer acetate. The secondary progressive multiple sclerosis patients group was not receiving any treatment. Our results reveal that the basal DNA damage was not different between relapsing-remitting and secondary progressive multiple sclerosis patients, and healthy controls. No differences between gamma-irradiation induced micronuclei frequencies in binucleated cells from relapsing-remitting and secondary progressive multiple sclerosis patients, and healthy controls were found either. Nevertheless, when we compared the radiation induced DNA damage in binucleated cells from healthy individuals with the whole group of patients, a reduction in the frequency of micronuclei was obtained in the patients group. Induced micronuclei yield was significantly lower in the irradiated samples from treated relapsing-remitting multiple sclerosis patients than in healthy controls and relapsing-remitting not treated patients. Intrinsic sensitivity of lymphocytes subpopulations to the apoptotic effect of immunomodulatory treatment could be responsible for this result.
authors.affiliation: III Neurological Clinic, University Hospital Saint Naum, Sofia, Bulgaria.
authors.forename: Maria
authors.initials: M
authors.lastname: Milenkova
authors.forename: Ivan
authors.initials: I
authors.lastname: Milanov
authors.forename: Ksenia
authors.initials: K
authors.lastname: Kmetska
authors.forename: Sofia
authors.initials: S
authors.lastname: Deleva
authors.forename: Ljubomira
authors.initials: L
authors.lastname: Popova
authors.forename: Valeria
authors.initials: V
authors.lastname: Hadjidekova
authors.forename: Violeta
authors.initials: V
authors.lastname: Groudeva
authors.forename: Savina
authors.initials: S
authors.lastname: Hadjidekova
authors.forename: Inmaculada
authors.initials: I
authors.lastname: Domínguez
mesh_terms: D000293:Adolescent; D000328:Adult; D016022:Case-Control Studies; D002478:Cells, Cultured; D002877:Chromosomes, Human / Q000528:radiation effects*; D005260:Female; D000068717:Glatiramer Acetate; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016899:Interferon-beta / Q000627:therapeutic use; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D008297:Male; D048629:Micronuclei, Chromosome-Defective / Q000187:drug effects / Q000528:radiation effects / Q000706:statistics & numerical data; D015162:Micronucleus Tests; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000097:blood / Q000188:drug therapy / Q000235:genetics / Q000503:physiopathology*; D010455:Peptides / Q000627:therapeutic use; D011836:Radiation Tolerance / Q000235:genetics*; D055815:Young Adult
chemical_list: D007166:Immunosuppressive Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta
keywords: Interferon β; Lymphocytes radiosensitivity; Micronuclei; Multiple sclerosis